drugset / Trial / NCT00061321

Daily Nevirapine to Prevent Mother to Infant Transmission of HIV

NCT00061321 ↗

RandomizedCrossoverOpen-labelPrevention

Summary

Infants who are breast-fed by HIV infected mothers have an increased risk of becoming infected with HIV. Standard therapy for the prevention of HIV infections in infants included zidovudine (ZDV) prior to the onset of labor, a single dose of nevirapine (NVP) for women during labor, and a single dose of NVP for newborns given 72 hours after birth. This study will determine if giving low dose daily NVP to breastfed infants of HIV infected mothers, in addition to standard therapy, will be more effective than standard therapy alone at preventing HIV infections in these infants.

Timeline

Start
2002-08
Primary completion
2007-04
Completion
2007-09

Outcome

Missed primary endpoint

paper At 6 months, 87 children in the single-dose group and 62 in the extended-dose group were infected with HIV (relative risk 0.80, 95% CI 0.58-1.10; p=0.16). PMID 18657709 ↗

paper the lack of a significant reduction in the primary endpoint-risk of HIV transmission at 6 months PMID 18657709 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nevirapine Small molecule 2 mg/kg Oral
Subject Nevirapine Small molecule 5 mg Oral
Subject Nevirapine Small molecule 200 mg Oral